Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine

Verburg, Frederik A.; Heinzel, Alexander; Hänscheid, Heribert; Mottaghy, Felix M.; Luster, Markus; Giovanella, Luca

doi:10.1007/s00259-013-2609-2

Cited by 15 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the introduction of the first PSMA tracer, several other PSMA ligands, labeled with 68 Ga or, as another approach, with 18 F, have been evaluated in a variety of studies for different disease settings of PCa. The possibility of labeling such tracers not only with diagnostic, but also with therapeutic radionuclides such as 177 Lutetium( 177 Lu, a beta emitter) or 225 Actinium( 225 Ac, an alpha emitter), allows additional use in a theranostic concept [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review

Lisney

Leitsmann

Strauß

et al. 2022

Cancers

View full text Add to dashboard Cite

The importance of PSMA PET/CT in both primary diagnostics and prostate cancer recurrence has grown steadily since its introduction more than a decade ago. Over the past years, a vast amount of data have been published on the diagnostic accuracy and the impact of PSMA PET/CT on patient management. Nevertheless, a large heterogeneity between studies has made reaching a consensus difficult; this review aims to provide a comprehensive clinical review of the available scientific literature, covering the currently known data on physiological and pathological PSMA expression, influencing factors, the differences and pitfalls of various tracers, as well as the clinical implications in initial TNM-staging and in the situation of biochemical recurrence. This review has the objective of providing a practical clinical overview of the advantages and disadvantages of the examination in various clinical situations and the body of knowledge available, as well as open questions still requiring further research.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review

Lisney

Leitsmann

Strauß

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Методы диагностики и лечения заболеваний щитовидной железы с помощью радиоактивного йода, разработанные S. Hertz, легли в основу нового направления клинической медицины -тераностики, которое в настоящее время получило широкое распространение [34][35][36][37]. Это понятие включает две основные категории, на которых фактически базируется современная медицина: терапия (англ.…”

Section: радиоактивный йод против рака щитовидной железыunclassified

Radioiodine therapy for thyroid cancer

Rybakov¹

2019

CE&ES

View full text Add to dashboard Cite

“…Theranostics refers to the use of individual patient-level biological information from imaging to determine an optimal therapy for an individual patient 1,2 . Thus, ideally, theranostic agents can be used for both, imaging and therapy to minimize changes in pharmacokinetics due to different chemical structures.…”

Section: Introductionmentioning

confidence: 99%

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model

Begum

Glatting

Wester

et al. 2019

Sci Rep

View full text Add to dashboard Cite

The aim of this work was to investigate the effect of ligand amount, affinity and internalization of prostate-specific membrane antigen (PSMA)-specific ligands on the activity concentrations for PET/CT imaging and on the absorbed doses for therapy. A physiologically-based pharmacokinetic (PBPK) model for PSMA-specific ligands was implemented. Thirteen virtual patients with metastatic castration-resistant prostate cancer were analysed. Simulations were performed for different combinations of association rates kon (0.1–0.01 L/nmol/min), dissociation rates koff (0.1–0.0001 min−1), internalization rates λint (0.01–0.0001 min−1) and ligand amounts (1–1000 nmol). For imaging the activity was normalized to volume and injected activity (68Ga-PSMA at 1 h). For therapy the absorbed dose was calculated for 7.3 ± 0.3 GBq 177Lu-PSMA. The effect of the investigated parameters on therapy were larger compared to imaging. For imaging, the combination of properties leading to the highest tumour uptake was kon = 0.1 L/nmol/min, koff = 0.01 min−1 for typical ligand amounts (1–10 nmol). For therapy, the higher the internalization rate, the larger was the required ligand amount for optimal tumour-to-kidney ratios. The higher the affinity, the more important was the choice of the optimal ligand amount. PBPK modelling provides insight into the pharmacokinetics of PSMA-specific ligands. Further in silico and in vivo studies are required to verify the influence of the analysed parameters.

show abstract

Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine

Cited by 15 publications

References 34 publications

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review

Radioiodine therapy for thyroid cancer

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model

Contact Info

Product

Resources

About